logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Novartis Gene Therapy Zolgensma Will Be Approved. The FDA Approves a Merck Combination for First-Line Renal cell Carcinoma. Regenxbio and Exelixis Are in Great Shape.

Zolgensma Findings The FDA submission of the gene therapy product Zolgensma was based on positive findings from a trial of 15 babies treated with it. Recently; however, at the Orlando meeting of the Muscular Dystrophy Association Novartis ( NVS )...

Read More

April 22, 2019

0

Amgen Has More Good News. What Is Going on with the CRISPR Gene Editing Firms?

A couple of days following the news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on  Amgen’s (AMGN)  product  Prolia ®  (denosumab)  for the treatment of  bone loss associated with...

Read More

May 1, 2018

0

Trovagene's News Is Encouraging

About Trovagene Trovagene ( TROV )  is still a clinical-stage company.  The p recision cancer medicine approach is practicing what it preaches right now in order to develop drugs that target cell division (mitosis) for: leukemias, lymphomas and solid tumor...

Read More

April 24, 2019

0

Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

NEKTAR Nektar Therapeutics (NKTR) and Takeda Pharmaceutical (TKPYY)   are collaborating to evaluate Nektar’s investigational medicine,  NKTR-214 , with Takeda’s investigational medicine,  TAK-659 ,  as a potential combination for multiple cancer settings.  NKTR-214  is an experimental immuno-stimulatory recognized to  expand specific cancer-fighting T cells...

Read More

April 26, 2018

0

Bayer Decision to Advance IONIS-FXI-LRx Following Positive Results. See Also: Why Hepion Pharmaceuticals Stock Almost Doubled Today

Bayer Decision to Advance IONIS-FXI-LRx for Clotting Disorders On October 9, 2019 Ionis Pharmaceuticals ( IONS ) announced it had been notified by its partner Bayer ( BAYN ) about the decision to advance IONIS-FXI-LRx  following positive clinical results. IONIS-FXI-LRx ...

Read More

October 17, 2019

0

Cures for Hemophilia A and B? See Also: Why EXEL Was a Loser Yesterday

SPARK THERAPEUTICS, SANGAMO THERAPEUTICS AND SALK INSTITUTE CURING HEMOPHILIA?   Hemophilia is an inherited bleeding disorder that causes abnormal or exaggerated bleeding and poor blood clotting. Hemophilia A and Hemophilia B are inherited in an X-linked recessive genetic pattern, so...

Read More

May 11, 2018

0

Trick or Trade?

The Misleading Market? The biotech stocks continue to begin their daily trading relying on opinionated articles implanted by bloggers on the Internet rather than on the firms’ voiced news.  It is unfortunate that we continue to observe many investors incapable...

Read More

April 26, 2019

0

Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target

Seattle Genetics Announced Positive Results for HER2CLIMB Trial Seattle Genetics ( SGEN ) announced positive topline results from the HER2CLIMB trial evaluating tucatinib in HER2- positive breast cancer .  The trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab...

Read More

October 21, 2019

0

The FDA Approval of Regeneron/Sanofi Praluent Is A Big Deal. Will the FDA Approve Nabriva Therapeutics’ Antibiotic Contepo Today?

Praluent's Approval Is a Big Deal The approval of the Regeneron / Sanofi s upplemental biological license application ( sBLA ) aimed at updating Praluent’s (alirocumab)  prescribing information is, indeed, a big deal. Proven life-saving benefits are confirmed. Comprising reducing...

Read More

April 30, 2019

0

News from PTC Therapeutics, Celgene and Heron Therapeutics

IN THE NEWS PTC THERAPEUTICS   PTC Therapeutics (PTCT)  stock, which dipped yesterday, probably on news announcing a public offering of 4,000,000 shares of its common stock at a public offering price of $27.04 per share. Yesterday, in a crazy market that...

Read More

March 29, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 72
  • 73
  • 74
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy